Drug Profile


Alternative Names: Benzoporphyrin derivative monoacid ring A; BPD; BPD-MA; CL 315555; CL 315585; CL 318952; Everteporfine; Verteporfin for injection - Novartis; Visudine; Visudyne

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of British Columbia
  • Developer Valeant Pharmaceuticals International
  • Class Antineoplastics; Eye disorder therapies; Porphyrins; Small molecules
  • Mechanism of Action Immunomodulators; Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Choroidal neovascularisation; Central serous chorioretinopathy; Age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration; Choroidal neovascularisation
  • No development reported Central serous chorioretinopathy
  • Discontinued Breast cancer; Coronary artery restenosis; Diabetic macular oedema; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Central serous chorioretinopathy in Canada (IV)
  • 16 Dec 2015 QLT files a breach of contract lawsuit against Valeant Pharmaceuticals in the Supreme Court of British Columbia
  • 24 Sep 2012 Valeant Pharmaceuticals acquires Verteporfin from its US owner, QLT
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top